Why Is Cancer-Focused Tyra Biosciences Stock Falling On Friday?
Tyra Biosciences released encouraging TYRA-300 data for metastatic urothelial cancer. 54.5% of patients at ≥ 90 mg QD achieved partial response. Overall, a 100% disease control rate was observed in patients receiving TYRA-300. Interim safety results showed TYRA-300 was well-tolerated with minimal serious adverse events. The stock price dropped 18.4% despite the positive clinical results.
View signal analysis